共 50 条
- [41] Pan-HER, an antibody mixture simultaneously targeting EGFR, HER2, and HER3, is highly effective in triple negative breast cancer patient-derived xenograftsCANCER RESEARCH, 2019, 79 (13)Rosato, Roberto R.Choi, Don S.Qian, WeiChen, WenLantto, JohanHorak, Ivan D.Kragh, MichaelChang, Jenny C.
- [42] Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast CancerMOLECULAR THERAPY-NUCLEIC ACIDS, 2018, 10 : 317 - 330Yu, XiaolinGhamande, SharadLiu, HaitaoXue, LuZhao, ShuhuaTan, WenxiZhao, LijingTang, Shou-ChingWu, DaqingKorkaya, HasanMaihle, Nita J.Liu, Hong Yan
- [43] Anti-tumor activity in preclinical models utilizing a conditional bispecific redirected activation molecule (COBRA) targeting Her2CANCER RESEARCH, 2024, 84 (07)Stringer, BradleyChouitar, JoharaCerbone, JacqualineFortin, SarahAinbinder, AlinaKysilovsky, CassieScott, BrittanyBanerjee, Antara
- [44] D3L-001, a novel bispecific antibody targeting HER2 and CD47, demonstrates potent preclinical efficacy in solid tumorsCANCER RESEARCH, 2023, 83 (07)Rui, HaopengYang, XiaofengChen, JiahaoWang, JiaZheng, ZhiqiangChen, ZhiqiangLu, JingtaoWu, PeggyChen, JanetWang, AllisonChen, George
- [45] BSI-730, a bispecific antibody targeting HER2 and PD-L1 for the development of a first-in-class bispecific ADCCANCER RESEARCH, 2024, 84 (06)Hao, XiaoyaoLi, HongyanLiu, Xiaodong F.Liu, JinyuDai, WenwenPan, YingHu, Hui-HanLi, JunXia, ShukaiLyu, QunDavis, Hugh M.Chen, MingjiuPeng, Zeyu
- [46] AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer modelsJournal of Experimental & Clinical Cancer Research, 33Zhaomei MuTeresa KlinowskaXiaoshen DongEmily FosterChris WomackSandra V FernandezMassimo Cristofanilli
- [47] AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer modelsJOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2014, 33Mu, ZhaomeiKlinowska, TeresaDong, XiaoshenFoster, EmilyWomack, ChrisFernandez, Sandra V.Cristofanilli, Massimo
- [48] Pan-HERAn antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimersINTERNATIONAL JOURNAL OF CANCER, 2016, 139 (09) : 2095 - 2105Ellebaek, SofieBrix, SusanneGrandal, MichaelLantto, JohanHorak, Ivan D.Kragh, MichaelPoulsen, Thomas Tuxen
- [49] HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activitiesCLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (04):Chu, WendiXu, HuiWang, YanfeiXie, YongleChen, Yi-LiTan, XiaorongHuang, ChenghaoWang, GuifengWang, QiLuo, WenxinXia, NingshaoGeng, MeiyuXie, ZuoquanWang, Chunhe
- [50] Preclinical development of a bispecific antibody-trap selectively targeting CD47 and HER2 for the treatment of breast as well as gastric cancerCANCER RESEARCH, 2022, 82 (12)Tian, WenzhiLi, SongChen, DianzeLiu, DandanGuo, HuiqinYang, ChunmeiZhang, LiZhang, WeiTu, XiaopingPeng, LiangZhao, GuiZhang, RuliangZhang, Fan